Is Forest Road Acquisition Corp. (FRX) a Buy, Sell, or Hold?
NYSE : FRX
Forest Road Acquisition Corp.
$12 USD
$0.78 (6.95%)
- Volume
- 3.96M
- Average Volume
- 1.57M
- Market Capitalization
- $3.75B
- P/E Ratio
- 6.82
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $18.20
- Year Low
- $9.24
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.79
Company Overview
NYSE
Zachary Tarica
Shell Companies
Financial Services
FRX
N/A
US
USD
Liquidity Metrics
0.09
0.79
0.61
0.44
0.00
Sales & Valuation
$251.73M
17.08
2.31
479.88
1.09
Profitability
-$0.41
-$2.86M
5.68%
5.74%
39.07%
9.13%
P/E Metrics
6.82
0.00
0.00
Analyst Price Target & Rating
0/5
2 Analysts
%
Financial Health Scores
17.46
6/9
-$15.58M
$136.51M
$99.32M
-$1.84M
Key Metrics (TTM)
$3.72B
16.95
641.86
0.79
39.07%
19.51%
14.52%
0.21%
$14.28
45 days
Company Executives
No executive data available.
Poll Results
No votes yet today — be the first to share your view!
About Forest Road Acquisition Corp. (NYSE:FRX) Stock
Forest Road Acquisition Corp., established in 2020 and headquartered in New York, New York, is focused on identifying and executing a strategic consolidation with one or more companies. The firm aims to complete various corporate transactions, including mergers, exchanges of capital stock, asset acquisitions, stock purchases, or other forms of corporate restructuring, specifically targeting the technology, media, and telecommunications sectors. ...
2026-07-28 03:23:51
Fennec Pharmaceuticals Inc. (TSE: FRX - Get Free Report) passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of C$13.94 and traded as high as C$14.65. Fennec Pharmaceuticals shares last traded at C$14.65, with a volume of 412 shares. Fennec Pharmaceuticals Trading Up 3.0% The company has
Fennec Announces Results of Annual Meeting
2026-06-10 16:30:00
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.
2026-05-21 18:01:00
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-18 16:30:00
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to purchase an aggregate of 859 shares. The Stock Options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
2026-05-14 12:20:42
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 06:30:00
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK ® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK ® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.
Frequently Asked Questions
-
What is the current Forest Road Acquisition Corp. (FRX) stock price?
-
Forest Road Acquisition Corp.(NYSE:FRX) stock price is $12 in the last trading session. During the trading session, FRX stock reached the peak price of $12.33 while $11.395 was the lowest point it dropped to. The percentage change in FRX stock occurred in the recent session was 6.95% while the dollar amount for the price change in FRX stock was $0.78.
-
FRX's industry and sector of operation?
-
The NYSE listed FRX is part of Shell Companies industry that operates in the broader Financial Services sector.
-
Who are the executives of FRX?
-
|
|
|
|
| -
How many employees does FRX have?
-
Number of FRX employees currently stands at None. FRX operates from 1177 Avenue of the Americas, New York City, NY , US.
-
Link for FRX official website?
-
Official Website of FRX is: http://www.spacroadone.com
-
How do I contact FRX?
-
FRX could be contacted at phone #917-310-3722 and can also be accessed through its website. FRX operates from 1177 Avenue of the Americas, New York City, NY , US.
-
How many shares of FRX are traded daily?
-
The average number of FRX shares traded daily for last 3 months was 1.57M.
-
What is the market cap of FRX currently?
-
The market value of FRX currently stands at $3.75B with its latest stock price at $12